Foot Health in People with Cancer Undergoing Chemotherapy: A Scoping Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Identifying the Research Question (Stage 1)
2.2. Identifying Relevant Studies (Stage 2)
2.3. Study Selection (Stage 3)
2.4. Charting the Data (Stage 4)
2.5. Collecting, Summarizing, and Reporting the Results (Stage 5)
3. Results
3.1. Bibliometric Characteristics
3.2. Methods of Collecting Information about the Foot
3.3. Main Objectives of the Documents Concerning the Foot
3.4. Findings from Thematic Analysis
3.4.1. Foot Health Adverse Events
3.4.2. Foot Health: A Critical Role Related to QoL of People Undergoing Anticancer Therapies
4. Discussion
4.1. Literature Gap from the Foot Health Perspective: A Challenge for Discussion
4.2. QoL of People with Cancer: An Agenda That Should Consider Foot Health
4.3. Future Lines of Research and Clinical Practice
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- National Cancer Institute. What Is Cancer? 2015. Available online: https://www.cancer.gov/about-cancer/understanding/what-is-cancer (accessed on 1 December 2022).
- World Health Organization. Cancer. 2018. Available online: https://www.who.int/es/news-room/fact-sheets/detail/cancer (accessed on 1 December 2022).
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Emine, K.E.; Gulbeyaz, C. The effect of salt-water bath in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane and platinum-based treatment. Explore 2022, 18, 347–356. [Google Scholar] [CrossRef]
- Kocarnik, J.M.; Compton, K.; Dean, F.E.; Fu, W.; Gaw, B.L.; Harvey, J.D.; Henrikson, H.J.; Lu, D.; Pennini, A.; Xu, R.; et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022, 8, 420–444. [Google Scholar] [PubMed]
- Hirose, C.; Fujii, H.; Iihara, H.; Ishihara, M.; Nawa-Nishigaki, M.; Kato-Hayashi, H.; Ohata, K.; Sekiya, K.; Kitahora, M.; Matsuhashi, N.; et al. Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy. Support. Care Cancer 2020, 28, 5943–5952. [Google Scholar] [CrossRef]
- Tachi, T.; Teramachi, H.; Tanaka, K.; Asano, S.; Osawa, T.; Kawashima, A.; Yasuda, M.; Mizui, T.; Nakada, T.; Noguchi, Y.; et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS ONE 2015, 10, e0124169. [Google Scholar] [CrossRef]
- Hagiwara, Y.; Shiroiwa, T.; Shimozuma, K.; Kawahara, T.; Uemura, Y.; Watanabe, T.; Taira, N.; Fukuda, T.; Ohashi, Y.; Mukai, H. Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study. Pharmacoeconomics 2018, 36, 215–223. [Google Scholar] [CrossRef]
- Stolt, M. Individual’s Foot Health. In Individualized Care: Theory, Measurement, Research and Practice, 1st ed.; Springer: Berlin/Heidelberg, Germany, 2019; pp. 163–169. [Google Scholar]
- Stolt, M.; Gattinger, H.; Boström, C.; Suhonen, R. Foot health educational interventions for patients and healthcare professionals: A scoping review. Health Educ. J. 2019, 79, 390–416. [Google Scholar] [CrossRef]
- López, P.P.; Rodríguez-Sanz, D.; Vallejo, R.B.D.B.; Losa-Iglesias, M.E.; Martín, J.G.; Lobo, C.C.; Lopez, D.L. Clinical aspects of foot health and their influence on quality of life among breast cancer survivors: A case–control study. Cancer Manag. Res. 2017, 9, 545–551. [Google Scholar] [CrossRef]
- Lacouture, M.E.; Kopsky, D.J.; Lilker, R.; Damstra, F.; van der Linden, M.H.M.; Freites-Martinez, A.; Nagel, M.P.M. Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors Awareness, Education, and Literature Review. J. Am. Podiatr. Med. Assoc. 2018, 108, 508–516. [Google Scholar] [CrossRef]
- Brodie, B.S. Health determinants and podiatry. Perspect. Public Health 2001, 121, 174–176. [Google Scholar] [CrossRef] [PubMed]
- Edwards, K.; Borthwick, A.; McCulloch, L.; Redmond, A.; Pinedo-Villanueva, R.; Prieto-Alhambra, D.; Judge, A.; Arden, N.; Bowen, C. Evidence for current recommendations concerning the management of foot health for people with chronic long-term conditions: A systematic review. J. Foot Ankle Res. 2017, 10, 51. [Google Scholar] [CrossRef] [PubMed]
- Williams, A.E.; Graham, A.S. ‘My feet-visible, but ignored.’ A qualitative study of foot care for people with rheumatoid arthritis. Clin. Rehabil. 2012, 26, 952–959. [Google Scholar] [CrossRef] [PubMed]
- Lazzarini, P.A.; Hurn, S.; Kuys, S.; Kamp, M.C.; Ng, V.; Thomas, C.; Jen, S.; Kinnear, E.M.; D’Emden, M.C.; Reed, L. Direct inpatient burden caused by foot-related conditions: A multisite point-prevalence study. BMJ Open 2016, 6, e010811. [Google Scholar] [CrossRef]
- Laitinen, A.-M.; Boström, C.; Hyytiä, S.; Stolt, M. Experiences of foot health in patients with rheumatoid arthritis: A qualitative study. Disabil. Rehabil. 2020, 44, 88–95. [Google Scholar] [CrossRef]
- Arksey, H.; O’Malley, L. Scoping studies: Towards a methodological framework. Int. J. Soc. Res. Methodol. 2005, 8, 19–32. [Google Scholar] [CrossRef]
- Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.K.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.J.; Horsley, T.; Weeks, L.; et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann. Intern. Med. 2018, 169, 467–473. [Google Scholar] [CrossRef]
- Levac, D.; Colquhoun, H.; O’Brien, K.K. Scoping studies: Advancing the methodology. Implement. Sci. 2010, 5, 69. [Google Scholar] [CrossRef]
- Peters, M.; Godfrey, C.; McInerney, P.; Munn, Z.; Trico, A.; Khalil, H. Chapter 11: Scoping Reviews. In JBI Manual for Evidence Synthesis; Aromataris, E., Munn, Z., Eds.; JBI: Long Beach, CA, USA, 2020. [Google Scholar]
- Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [Google Scholar] [CrossRef]
- Komatsu, H.; Yagasaki, K.; Hirata, K.; Hamamoto, Y. Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study. Eur. J. Oncol. Nurs. 2018, 38, 65–69. [Google Scholar] [CrossRef]
- Hsu, Y.-H.; Shen, W.-C.; Wang, C.-H.; Lin, Y.-F.; Chen, S.-C. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy. Eur. J. Oncol. Nurs. 2019, 43, 101670. [Google Scholar] [CrossRef] [PubMed]
- Urakawa, R.; Tarutani, M.; Kubota, K.; Uejima, E. Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy. J. Cancer 2019, 10, 4846–4851. [Google Scholar] [CrossRef] [PubMed]
- Biswal, S.G.; Mehta, R.D. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian J. Dermatol. 2018, 63, 41–46. [Google Scholar] [CrossRef] [PubMed]
- Monfort, S.M.; Pan, X.; Patrick, R.; Ramaswamy, B.; Wesolowski, R.; Naughton, M.J.; Loprinzi, C.L.; Chaudhari, A.M.W.; Lustberg, M.B. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res. Treat. 2017, 164, 69–77. [Google Scholar] [CrossRef]
- Winther, D.; Saunte, D.M.; Knap, M.; Haahr, V.; Jensen, A.B. Nail changes due to docetaxel—A neglected side effect and nuisance for the patient. Support. Care Cancer 2007, 15, 1191–1197. [Google Scholar] [CrossRef] [PubMed]
- Gilbar, P.; Hain, A.; Peereboom, V.-M. Nail Toxicity Induced by Cancer Chemotherapy. J. Oncol. Pharm. Pract. 2009, 15, 143–155. [Google Scholar] [CrossRef]
- Engvall, K.; Gréen, H.; Fredrikson, M.; Lagerlund, M.; Lewin, F.; Åvall-Lundqvist, E. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: A population-based cross-sectional study. Breast Cancer Res. Treat. 2022, 195, 379–391. [Google Scholar] [CrossRef]
- Miller, K.K.; Gorcey, L.; McLellan, B.N. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J. Am. Acad. Dermatol. 2014, 71, 787–794. [Google Scholar] [CrossRef]
- Hawke, F.; Burns, J.; Landorf, K.B. Evidence-based podiatric medicine. J. Am. Podiatr. Med. Assoc. 2009, 99, 260–266. [Google Scholar] [CrossRef]
- López-López, D.; Pérez-Ríos, M.; Ruano-Ravina, A.; Losa-Iglesias, M.E.; Becerro-De-Bengoa-Vallejo, R.; Romero-Morales, C.; Calvo-Lobo, C.; Navarro-Flores, E. Impact of quality of life related to foot problems: A case–control study. Sci. Rep. 2021, 11, 1–6. [Google Scholar] [CrossRef]
- Grenon, N.N. Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer. Clin. J. Oncol. Nurs. 2013, 17, 425–433. [Google Scholar] [CrossRef] [PubMed]
- Zawar, V.; Bondarde, S.; Pawar, M.; Sankalecha, S. Nail changes due to chemotherapy: A prospective observational study of 129 patients. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 1398–1404. [Google Scholar] [CrossRef] [PubMed]
- Ding, J.F.; Farah, M.H.; Nayfeh, T.; Malandris, K.; Manolopoulos, A.; Ginex, P.K.; Hasan, B.; Dunnack, H.; Abd-Rabu, R.; Rajjoub, M.R.; et al. Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis. Oncol. Nurs. Forum 2020, 47, E149–E160. [Google Scholar] [CrossRef] [PubMed]
- Alizadeh, N.; Mirpour, S.H.; Darjani, A.; Rafiei, R.; Rafiei, E.; Mohammadhoseini, M. Dermatologic adverse effects of breast cancer chemotherapy: A longitudinal prospective observational study with a review of literature. Int. J. Dermatol. 2020, 59, 822–828. [Google Scholar] [CrossRef]
- Lambert-Falls, R.; Modugno, S. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study. Clin. Breast Cancer 2007, 7, 697–704. [Google Scholar] [CrossRef]
- Viale, P.H. Chemotherapy and Cutaneous Toxicities: Implications for Oncology Nurses. Semin. Oncol. Nurs. 2006, 22, 144–151. [Google Scholar] [CrossRef]
- Zaiem, A.; Hammamia, S.; Aouinti, I.; Charfi, O.; Ladhari, W.; Kastalli, S.; El Aidli, S.; Lakhoua, G. Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review. Indian J. Pharmacol. 2022, 54, 208–215. [Google Scholar]
- Veiga-Seijo, R.; Perez-Lopez, M.E.; Fernandez-Lopez, U.; Mosquera-Fernandez, A.; Seijo-Bestilleiro, R.; Gonzalez-Martin, C. Wellbeing and Complementary Therapies in Breast Cancer Peripheral Neuropathy Care: A Scoping Review Focused on Foot Health. Cancers 2023, 15, 2110. [Google Scholar] [CrossRef]
- Gu, J.; Lu, H.; Chen, C.; Gu, Z.; Hu, M.; Liu, L.; Yu, J.; Wei, G.; Huo, J. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: A meta-analysis. Support. Care Cancer 2021, 29, 7461–7469. [Google Scholar] [CrossRef]
- Shah-Hamilton, A. The impact of anti-cancer treatment on feet. Podiatric Adverse Events: Part 2a Neurological Effects. Podiatry Rev. 2021, 2, 26–29. [Google Scholar]
- Shah-Hamilton, A. The impact of anti-cancer treatment on feet. Podiatric Adverse Events: Part 2b Dermatological Effects. Podiatry Rev. 2021, 1, 32–36. [Google Scholar]
- Rustøen, T. Hope and quality of life, two central issues for cancer patients: A theoretical analysis. Cancer Nurs. 1995, 18, 355–361. Available online: http://www.ncbi.nlm.nih.gov/pubmed/7585489 (accessed on 1 December 2022). [PubMed]
- Ganz, P.A.; Dougherty, P.M. Painful Hands and Feet After Cancer Treatment: Inflammation Affecting the Mind-Body Connection. J. Clin. Oncol. 2016, 34, 649–652. [Google Scholar] [CrossRef] [PubMed]
- Anderson, R.T.; Keating, K.N.; Doll, H.A.; Camacho, F. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist 2015, 20, 831–838. [Google Scholar] [CrossRef] [PubMed]
- Dar, W.; Hussain, M.; Aziz, S.A.; Mohammad, G.; Wani, B.; Latief, M. Uncommon adverse effects of commonly used chemotherapeutic agents in medical oncology practice: A series of two cases of hand-foot syndrome. Indian. J. Med. Paediatr. Oncol. 2017, 38, 380–382. [Google Scholar] [CrossRef]
- Bao, T.; Basal, C.; Seluzicki, C.; Li, S.Q.; Seidman, A.D.; Mao, J.J. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk. Breast Cancer Res. Treat. 2016, 159, 327–333. [Google Scholar] [CrossRef]
- Mizrahi, D.; Goldstein, D.; Trinh, T.; Li, T.; Timmins, H.C.; Harrison, M.; Marx, G.M.; Hovey, E.J.; Lewis, C.R.; Friedlander, M.; et al. Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy. Asia-Pac. J. Clin. Oncol. 2022, 19, 243–249. [Google Scholar] [CrossRef]
- Simsek, N.Y.; Demir, A. Cold Application and Exercise on Development of Peripheral Neuropathy during Taxane Chemotherapy in Breast Cancer Patients: A Randomized Controlled Trial. Asia-Pac. J. Oncol. Nurs. 2021, 8, 255–268. [Google Scholar] [CrossRef]
- Williams, L.A.; Ginex, P.K.; Ebanks, G.L.; Ganstwig, K.; Ciccolini, K.; Kwong, B.Y.; Robison, J.; Shelton, G.; Strelo, J.; Wiley, K.; et al. ONS guidelinesTM for cancer treatment-related skin toxicity. Oncol. Nurs. Forum. 2020, 47, 539–556. [Google Scholar] [CrossRef]
- Velasco, R.; Navarro, X.; Gil-Gil, M.; Herrando-Grabulosa, M.; Calls, A.; Bruna, J. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. J. Pain. Symptom Manag. 2017, 54, 815–825. [Google Scholar] [CrossRef]
- Kevin, D.; Brabants, A.; Nester, C.; Gijon-Nogueron, G.; Simşek, E.; Newton, V. A conceptual framework for contemporary professional foot care practice: “The value based digital foot care framework”. J. Foot Ankle Res. 2021, 14, 22. [Google Scholar] [CrossRef]
Concept | Search Terms |
---|---|
Foot | Foot OR podiatry OR “hand–foot syndrome” OR “foot diseases” OR “foot health” |
Cancer | Neoplasm OR cancer |
Chemotherapy | “Drug therapy” OR “chemotherapy” |
First Author, Year, Country (Health Professional Department) | Journal | Sample | Anticancer Therapies | Type of Study | Research Objectives | Data Collection Methods Concerning Foot | Was the Aim of the Study the Foot Health? | Studied Foot Health Problems Related QoL | Main Findings |
---|---|---|---|---|---|---|---|---|---|
| |||||||||
Lacouture et al. [13], 2018, USA (Department of Oncology and Podiatry) | Journal of the American Podiatric Medical Association | n = 291 Breast (40.2%), colon (10.3%) | Cytotoxic chemotherapy, targeted therapy, radiation therapy, surgical procedures, and stem cell transplants | Clinical experience and literature review | To show the impact of podiatric adverse events on QoL in an Oncology Foot Care Program and to review podiatric adverse events related to cancer treatments. | NCICTCAE | Yes | Yes |
|
Komatsu et al. [24], 2019, Japan, Yagasaki, Hirata, and Hamamoto (Department of Nursing) | European Journal of Oncology Nursing | n = 20 (13 female, 7 male) colon (65%), gastric (20%) cancer | Chemotherapy and targeted therapy | Qualitative study | To understand the perceived needs of advanced-stage cancer patients with chemotherapy-related hand–foot syndrome and/or targeted therapy-related hand–foot skin reactions. | Interviews | Focused on HFS | Yes |
|
Hsu et al. [25], 2019, Taiwan (Department of Nursing) | European Journal of Oncology Nursing | n = 85 breast cancer (100% female) | Docetaxel-based chemotherapy | Cross-sectional, descriptive, and correlational designs | (1) to assess breast cancer patients’ perceived levels of HFS-related foot symptoms, HFS-related hand or finger symptoms, and HFS-related restrictions in daily activities, and (2) to identify factors associated with HFS-related restrictions in daily activities. | Hand–Foot Quality of Life Scale (HF QoLS) symptom subscale questionnaire HF QoLS—daily activity subscale NCICTCAE | Focused on Hand–Foot Syndrome | Yes |
|
Miller et al. [32], 2014, USA (Department of Dermatology) | Journal of the American Academy of Dermatology | Breast cancer | Different chemotherapy agents and targeted multikinase inhibitors | Review | To describe the epidemiology, pathogenesis, clinical presentation, and current evidence-based treatment for chemotherapy-induced hand–foot syndrome and nail changes. | HFS: National Cancer Institute Criteria for its classification and World Health Organization criteria Nail: NCICTCAE | Focused on Hand–Foot Syndrome and nail changes (both hand and foot) | Yes |
|
Gilbar et al. [30], 2009, Australia (Department of Pharmacology) | Journal of Oncology Pharmacy Practice | Articles about breast, lung, ovarian, and colon cancer, melanoma, Hodgkin, and carcinoid tumors | Different chemotherapy agents | Literature Review | To provide a comprehensive literature review of chemotherapy-induced nail toxicity (presentation, implication, drugs, and approaches for prevention and management). | NCICTCAE | Focused on nails (both hand and foot) | No |
|
Palomo-López et al. [12], 2017, Spain (Department of Nursing and Podiatry) | Cancer Management and Research | n = 200 100% women (50% breast cancer, 50% without cancer) | Chemotherapy treatment | Case-control observational | To analyze and compare foot health and general health in a sample of women with breast cancer and healthy women. | Foot Health Status Questionnaire and podiatric assessment | Yes | Yes |
|
Engvall et al. [31], 2022, Sweden (Department of Oncology and Pharmacology) | Breast Cancer Research and Treatment | 646 survivors of breast cancer | Post-taxane treatment | Cross-sectional cohort study | To explore the impact of persistent sensory and motor taxane-induced peripheral neuropathy symptoms on health-related QoL among early-stage breast cancer survivors. | EORTC QLQ-C30, HADS, CIPN20 | Focused on peripheral neuropathy | Yes |
|
Winther et al. [29], 2007, Denmark (Department of Oncology) | Supportive Care Cancer | n = 55 breast cancer | Chemotherapy treatment (docetaxel) | Observational and prevalence study | To estimate the frequency and severity of nail changes due to treatment. | NCICTCAE | No (nails, both hands and feet) | Yes |
|
Monfort et al. [28], 2017, United States (Department of Oncology, biostatistics, engineering) | Breast Cancer Research and Treatment | n = 33 breast cancer patients (32 female/1 male) | Taxane | Longitudinal study | To describe symptoms of CIPN and functional impairments. | Standing balance, gait, Modified Total Neuropathy Score, Patient Report Outcomes (EORTC QLQ-CIPN20, EORTC QLQ-C30, BPI-SF) | No (peripheral neuropathy—gait) | Yes |
|
Biswal et al. [27], 2018, India (Deparment of Dermatology) | Indian Journal of Dermatology | n = 1000 Different tumor (24.1% genitourinary, 14.7% breast) | Chemotherapy drugs in combination (mostly alkylating agents) | Observational study | To know the cutaneous adversities in patients undergoing chemotherapy and the drug(s) most commonly associated with them. | Clinical manifestations | No (cutaneous adversities) | No |
|
Urakawa, et al. [26], 2019, Japan (Department of Dermatology and Pharmacology) | Journal of Cancer | n = 67 Cancer patients | Skin-toxic chemotherapeutic agents | Cross-sectional study | To investigate which skin toxicities influenced QoL and to what extent. | NCICTCAE, Dermatology Life Quality Index, and Skindex | No (skin toxicities) | Yes |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Veiga-Seijo, R.; Gonzalez-Martin, C. Foot Health in People with Cancer Undergoing Chemotherapy: A Scoping Review. Healthcare 2023, 11, 1588. https://doi.org/10.3390/healthcare11111588
Veiga-Seijo R, Gonzalez-Martin C. Foot Health in People with Cancer Undergoing Chemotherapy: A Scoping Review. Healthcare. 2023; 11(11):1588. https://doi.org/10.3390/healthcare11111588
Chicago/Turabian StyleVeiga-Seijo, Raquel, and Cristina Gonzalez-Martin. 2023. "Foot Health in People with Cancer Undergoing Chemotherapy: A Scoping Review" Healthcare 11, no. 11: 1588. https://doi.org/10.3390/healthcare11111588